Column Capital Advisors’s Gilead Sciences GILD Stock Holding History

Column Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$27.1K	Sell	362 -11	-3%	-$846	﹤0.01%	404
2023 Q2	$28.7K	Sell	373 -21	-5%	-$1.68K	﹤0.01%	395
2023 Q1	$32.7K	Hold	394	–	–	﹤0.01%	375
2022 Q4	$33.8K	Hold	394	–	–	0.01%	354
2022 Q3	$24K	Hold	394	–	–	0.01%	363
2022 Q2	$24K	Hold	394	–	–	﹤0.01%	371
2022 Q1	$23K	Sell	394 -9	-2%	-$575	﹤0.01%	388
2021 Q4	$29K	Sell	403 -21	-5%	-$1.45K	0.01%	376
2021 Q3	$30K	Sell	424 -16	-4%	-$1.12K	0.01%	343
2021 Q2	$30K	Sell	440 -803	-65%	-$53.6K	0.01%	336
2021 Q1	$80K	Hold	1,243	–	–	0.02%	207
2020 Q4	$72K	Hold	1,243	–	–	0.02%	216
2020 Q3	$79K	Hold	1,243	–	–	0.02%	181
2020 Q2	$95K	Sell	1,243 -14	-1%	-$1.07K	0.03%	156
2020 Q1	$94K	Sell	1,257 -20	-2%	-$1.38K	0.04%	130
2019 Q4	$82K	Buy	+1,277	New	+$83.2K	0.04%	171

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Column Capital Advisors's GILD Position: Q3 2023 in Review

Column Capital Advisors reduced its Gilead Sciences (GILD) stake by 2.9% in Q3 2023, selling an estimated $846 and leaving 362 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #404.

Column Capital Advisors first reported a position in GILD in Q4 2019 and has held it in 16 quarters since. The position peaked at $95K in Q2 2020. 1,683 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

Column Capital Advisors held 362 shares of Gilead Sciences worth $27.1K as of Q3 2023.
Column Capital Advisors sold 11 Gilead Sciences shares in Q3 2023, an estimated $846.
Gilead Sciences made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #404 holding.
Column Capital Advisors first reported a position in Gilead Sciences in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Gilead Sciences position peaked at $95K in Q2 2020.
1,683 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.